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Recent studies have found that asthmatic women pregnant with a female fetus reported more
symptoms and had slightly lower lung function than women pregnant with a male fetus. In
order to further investigate this association, we studied the effect of fetal sex on maternal
asthma exacerbations and the use of asthma medications during pregnancy. A large cohort
of pregnant asthmatic women and their babies was reconstructed between 1990 and 2002 from
the linkage of three administrative databases of the Canadian province of Quebec. Asthma
exacerbations were defined as a filled prescription of oral corticosteroids, an emergency
department visit, or a hospitalization for asthma. Women pregnant with a female fetus were
compared to women with a male fetus with respect to their rate of asthma exacerbation, their
weekly doses of inhaled short-acting beta2-agonists (SABA), and their daily dose of inhaled
corticosteroids (ICS) during pregnancy. Logistic and linear regression models were used to
obtain effect measures adjusted for several potential confounders such as asthma severity
and control prior to pregnancy. The cohort included 5529 pregnancies with a single female
fetus and 5728 pregnancies with a single male fetus. No significant differences were found
between mothers of a female and male fetus as to the occurrence of asthma exacerbations
(adjusted rate ratioZ 1.02; 95% CI: 0.92e1.14), the daily dose of ICS (adjusted mean differ-
ence (AMD): 2.46 mg; 95% CI: 4.01 to 8.93), and the weekly dose of SABA (AMD: 0.004 dose;
95% CI: 0.23 to 0.24). Based on the results, we conclude that fetal gender is unlikely to affect
maternal asthma during pregnancy to the point where acute care and medications are more
often required among women pregnant with a female fetus.
ª 2008 Elsevier Ltd. All rights reserved.Pharmacie, Universite´ de Montre´al, C.P. 6128, Succursale Centre-Ville, Montre´al, Que´bec H3C 3J7,
; fax: þ1 514 343 6120.
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The prevalence of asthma among pregnant women varies
between 4 and 7% and it is known as one of themost frequent
chronic diseases encountered during pregnancy.1e5 The
course of asthmamay remain unchanged, improve or worsen
during pregnancy and usually returns to the pre-pregnancy
state within three months after delivery.6,7 The control of
asthma during pregnancy can be influenced by several
factors, namely physiologic hormonal changes that are
triggered during pregnancy.7
A few studies have suggested that a pregnant woman’s
asthma may worsen when carrying a female fetus.8e11 In
a review of case series,11 three mothers who had been
followed in successive pregnancies reported more asthma
attacks when pregnant with a female fetus than when they
were carrying a male fetus. Moreover and in comparison
with mothers carrying a male fetus, Beecroft et al.
observed that pregnant asthmatic mothers with a female
fetus had reported an increase in asthma symptoms8 while
Dodds et al.9 observed that they had an increased usage of
steroids. More recently, Kwon et al. assessed the associa-
tion between fetal gender and airway lability among
pregnant asthmatic women and found a 10% significant
reduction in peak expiratory flow rate (PEF) among mothers
with a female fetus. Conversely, Baibergenova et al. did not
find any significant association between fetal gender and
visits to an emergency department (ED) for asthma during
pregnancy.12 Among the hypotheses put forward to explain
the mechanisms behind the association between fetal
gender and maternal asthma control during pregnancy, the
one related to the regulation of placental glucocorticoid
and immune response in asthmatic pregnancies seems the
most plausible.8,10,12 Indeed, Clifton and Murphy and their
research teams have reported that female fetus alters
maternal asthma during pregnancy by upregulating
maternal inflammatory pathways13e16 and thus if asthma-
associated inflammatory pathways are not treated with
inhaled steroids during pregnancy, the mother could suffer
from asthma exacerbation.
Although studies have reported possible associations
between fetal gender and maternal asthma control during
pregnancy, methodological issues such as themeasure of the
outcome and the absence of statistical inference, as well as
the questionable clinical significance of some of the results
make it difficult to conclude with a reasonable degree of
certainty that women pregnant with a female fetus aremore
likely to have uncontrolled asthma. Using Canadian admin-
istrative databases, we planned a large cohort study to
further evaluate the effect of fetal gender on the risk of
uncontrolled maternal asthma through the study of exacer-
bations, use of inhaled short-acting beta2-agonists (SABA)
and inhaled corticosteroids (ICS) during pregnancy.
Materials and methods
Source of data
The data for our study came from three administrative
databases of the Canadian province of Que´bec; the Re´gie
de l’Assurance Maladie du Que´bec (RAMQ), MED-ECHO, andthe Fichier des e´ve´nements de´mographiques du Que´bec
(birth and death registries) managed by the Institut de la
statistique du Que´bec (ISQ). RAMQ databases provide
information on the medical services dispensed to all resi-
dents of Que´bec and on prescribed medications filled in
community pharmacies by residents covered by the RAMQ’s
Public Drug Insurance Plan. Approximately 43% of the
population of Quebec is covered by the RAMQ Public Drug
Insurance Plan, most notably the elderly and social aid
beneficiaries since 1980 and since 1997, 1.7 million new
adherents, mainly workers and their families who have no
access to a private drug insurance plan.17 The RAMQ’s
Prescription Drug Insurance database provides information
on dispensed medications e i.e. date of filling, name, dose,
quantity, dosage form and duration of the prescription e
while the RAMQ’s Medical Services database provides
information on medical services dispensed in a clinic, an
emergency department (ED) or a hospital (date, diagnosis
coded with ICD-9, where the service was dispensed, etc.).
The RAMQ databases also provide socio-demographic data
such as age, gender, social assistance status and where
relevant, date of death. Data recorded in the RAMQ
Prescription Drug Insurance database and asthma diagnoses
recorded in the RAMQ Medical Services database have been
formally evaluated and found to be valid.18,19 The MED-
ECHO database is a provincial database which records data
on acute care hospitalizations and covers all residents of
Quebec. For each hospitalization, data on primary and up
to 15 secondary discharge diagnoses, date of entry, dura-
tion of hospitalization, and treatments received during the
hospitalization are available.19 The Fichier des e´ve´nements
de´mographiques provides information on all births and
stillbirths in the province of Que´bec.Study design and population
A large cohort of pregnant asthmatic women and their
babies was reconstructed between 1990 and 2002 from the
linkage of the three administrative databases. Pregnant
women were identified using diagnostic and act codes
related to prenatal care, pregnancy complications, abor-
tions and deliveries.20 To be included in our cohort,
a woman should have: (1) had one or more singleton preg-
nancies ending in a delivery (life birth or stillbirth) between
January 1, 1990 and December 31, 2002; (2) been between
13 and 50 years of age at conception; (3) had in the two
years prior to, or during pregnancy, a diagnosis of asthma
(9th international classification of diseases (ICD-9) code
493, except 493.2 which relates to COPD disease) and one
or more prescriptions for an asthma medication (ICS, oral
corticosteroids, SABA, long-acting beta2-agonists (LABA),
theophyllines, leukotriene-receptor antagonists, inhaled
short-acting anticholinergic, cromoglycate or nedocromil)
dispensed; (4) had coverage with the RAMQ Drug Insurance
Plan for at least one year prior to, and throughout the
duration of pregnancy; and (5) had no other pregnancy of
more than 14 weeks in the year prior to conception. The
length of gestation was obtained mainly from the MED-
ECHO database, which was calculated based upon the date
of the last menstruation. To assess the date of conception,
we subtracted the length of gestation from the date of the
146 F. Firoozi et al.delivery. The unit of analysis was pregnancy; a woman
could contribute more than one pregnancy in the cohort.
For each included woman, data from RAMQ and MED-
ECHO were obtained for the two years preceding concep-
tion, and the duration of the pregnancy. This motherechild
cohort was then linked with the Fichier des e´ve´nements
de´mographiques databases to obtain information on socio-
demographic variables for the mothers and the newborns.
Fetal gender
The gender of the baby was extracted from the RAMQ
database and was checked for consistency with that recor-
ded in the ISQ and MED-ECHO databases. In case of missing
values or inconsistencies, the following algorithm was used
to determine the gender: (1) if the gender of the baby was
recorded in the RAMQ database then this value was retained;
(2) if the gender of the baby was missing at RAMQ and
recorded at ISQ then the ISQ value was retained; and (3) if
the gender of the baby was missing at RAMQ and ISQ, the
value recorded at MED-ECHO was retained. If the gender of
the baby was not recorded in any of the three databases, the
pregnancy was excluded. Fetal gender has been formally
evaluated and found to be highly valid as compared to the
information recorded in the medical chart of the mother
with specificity and sensitivity higher than 0.97.21
Primary and secondary outcomes
The primary outcome was asthma exacerbations during
pregnancy. Based upon the criteria used in the Canadian
Asthma Consensus Guidelines, asthma exacerbations were
defined as a short (14 days) course of oral corticosteroids
dispensed by a pharmacy, an ED visit for asthma, or a hospi-
talization for asthma.22 To avoid the overestimation of the
number of exacerbations, all the aforementioned events
occurring within a 15-day period accounted for one exacer-
bation. Asthma diagnoses recorded in the RAMQ databases
have been formally evaluated and found to be valid.19
The secondary outcomes included the mean daily dose of
ICS and the mean weekly dose of SABA during pregnancy,
calculated using data from the RAMQ’s database using
validated algorithms based upon the name, dose, formula-
tion and quantity of the dispensed medication, duration of
the prescription and time intervals between renewals.20,23
The equivalencies of the mean daily dose of ICS into
beclomethasone-CFC were calculated using the equivalency
table published in the Canadian Asthma Consensus Guide-
lines.22 The equivalencies for SABA were established by
a pharmacist (MFB); for example, one dose of SABA was
equivalent to two inhalations of salbutamol from ametered-
dose inhaler (100 mg per inhalation).23
Data analysis
Descriptive statistics were calculated by fetal gender for
socio-demographic variables, antiasthmatic medication
use, and health care services use for asthma during preg-
nancy. Crude rates of maternal asthma exacerbation during
the whole pregnancy and for each trimester separately
were compared between pregnancies of a female and male
fetus.Logistic regression models were used to obtain odds
ratios of exacerbation adjusted for several potential
confounders including socio-demographic variables such as
maternal age at conception (<18, 18e34, >34 years), social
assistance benefits one year before or during pregnancy
(yes/no), area of residency at delivery (rural or urban);
pregnancy related variables such as being primiparous (yes/
no), high risk pregnancy (yes/no), gestational diabetes
(yes/no), diabetes mellitus (yes/no), pregnancy induced
hypertension (yes/no), chronic hypertension (yes/no),
gynecologist or obstetrician visit during pregnancy (yes/
no), number of prenatal visits (5, 6e14, >14); as well as
asthma related variables such as a respiratory specialist
visit during pregnancy (yes/no), ICS use during pregnancy
(yes/no), and asthma severity and control prior to preg-
nancy. Asthma severity and control were measured with
validated database indexes that we developed based on
medication use and the need for acute care for asthma.24
We used a backward elimination strategy to find final
logistic regression models including covariates that changed
the odds ratio associated with the gender of the baby by at
least 10% and covariates that were found to be statistically
associated with the outcome. Adjusted effects of fetal
gender were estimated for the whole pregnancy and for
each trimester separately. The first, second and third
trimesters of pregnancy were defined as periods between
0 and 14 weeks of pregnancy, between 15 and 28 weeks of
pregnancy and from the 29th week up to the end of preg-
nancy, respectively.
Adjusted differences in the mean daily dose of ICS and
mean weekly dose of SABA were estimated between all
pregnancies of female and male fetuses using linear
regression models and the aforementioned potential
confounders. Adjusted differences were estimated for the
whole pregnancy and for each trimester separately.
One secondary analysis was performed on the primary
outcome. For this analysis, we selected the women who
had at least two pregnancies during the study period with
fetuses of different sex. For these women, the rate of
asthma exacerbations during the whole pregnancy was
compared between pregnancies of a female and male fetus
using logistic regression models. All statistical analyses
were performed using SAS version 8.02.
Results
Study population characteristics
Among the 13 040 pregnancies included in the cohort of
asthmatic women, 1774 were excluded because there was
another pregnancy of 14 weeks or more in the year prior to
conception and nine pregnancies were excluded because
the baby’s gender was unknown. The final cohort included
11 257 singleton pregnancies with 5529 female (49.1%) and
5728 male (50.9%) fetuses. The rate of concordance for
fetal gender between the three databases was 99%.
In Table 1, we present the socio-demographic and preg-
nancy related characteristics of the study women, by fetal
gender. The female and male fetus groups showed compa-
rable characteristics. In Table 2, we present the asthma
related characteristics in the year before conception and
Table 1 Socio-demographic and pregnancy related
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Chronic hypertension, % 2.6 2.3
Gynecologist or
obstetrician












a Recipient of social assistance in the year prior to or during
pregnancy.
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distributed similarly among female and male fetus preg-
nancies for these two periods.
Maternal asthma exacerbation during pregnancy by
fetal gender
In Table 3, we present the proportion of women who had at
least one asthma exacerbation within each trimester
separately and during the entire pregnancy, by fetal
gender. During the first trimester, 6.9% and 6.8% of women
carrying a female and male fetus had at least one asthma
exacerbation, respectively. In the second trimester, this
proportion remained unchanged for the female fetus group,
but increased modestly to 7.1% for the male fetus group.
During the third trimester, the rate of maternal asthma
exacerbations decreased to 4.0% and 3.7% for mothers of
female and male fetuses, respectively. The final logistic
regression models showed no statistically significant
differences in the rate of exacerbation both during the
entire pregnancy and for each trimester separately
between mothers of female and male fetuses after
adjusting for all potential confounders listed in the data
analysis section (adjusted rate ratioZ 1.02; 95% CI: 0.92e
1.14 for the entire pregnancy).Maternal SABA use by fetal gender
In Table 4, we present the results of the analyses performed
to compare the use of SABA between women pregnant with
female and male fetuses. The mean doses of SABA used per
week in each trimester and during the entire pregnancy
were similar in both groups. Moreover, the proportion of
women who used at least one dose of SABA per week on
average during the entire pregnancy was similar between
the groups (62.5% for female and 62.6% for male fetuses).
No statistically significant adjusted differences were found
between mothers of female and male fetuses as to their use
of SABA (adjusted mean difference: 0.004 dose per week;
95% CI: 0.23; 0.24 for the entire pregnancy).
Maternal ICS use by fetal gender
In Table 5, we present the results of the analysis comparing
the mean daily dose of ICS between women pregnant with
female and male fetuses. Similar proportions of women
used ICS in each trimester and during the entire pregnancy
in both groups (41.6% in female and 41.0% in male fetuses
during the entire pregnancy). Moreover, the daily doses of
ICS were similar between the groups. No statistically
significant adjusted differences were found between
mothers of female and male fetuses as to their use of ICS
(adjusted mean difference: 2.46 mg per day; 95% CI: 4.01;
8.93 for the entire pregnancy).
Maternal asthma exacerbations in successive
pregnancies with a different fetal gender
From the cohort of 11 257 asthmatic pregnant women, we
identified 1674 women who had more than one pregnancy
during the study period. Among them, 874 had one delivery
with a girl and one delivery with a boy during the study
period. There was no significant difference in the rate of
asthma exacerbations during the entire pregnancy between
the male and female fetuses (adjusted rate ratioZ 1.07;
95% CI: 0.81e1.42).
Discussion
In this large cohort study of 11 257 pregnancies of asthmatic
women, we detected no significant increase in the rate of
maternal asthma exacerbations, the use of ICS and SABA
during pregnancy among mothers of female fetuses,
whether examined between or within mothers.
Our results are in concord with those of Baibergenova
et al. who found no difference in ED visits for asthma
between pregnancies of male and female fetuses. This
study was based on a large cohort of 109 173 live singleton
deliveries reconstructed from a hospital and an ambulatory
care administrative database provided by the Canadian
Institute for Health Information (CIHI). From this cohort,
the investigators first identified all patients who visited an
ED during pregnancy and then found that 0.49% and 0.48%
of those ED visits were for asthma among women pregnant
with a female and a male fetus, respectively (p value
>0.05). However, these results should be interpreted with
caution since the authors did not take into account the
Table 2 Asthma related characteristics of study women by fetal gender.













ICS use (mg per day),a %
0 56.0 55.3 58.4 59.0
0e500 40.3 41.3 37.6 37.6
500e1000 2.6 2.4 3.0 2.2
>1000 1.1 0.9 1.0 1.2
SABA useb
(number of doses per week), %
0 33.4 32.9 37.5 37.5
>0e3 34.9 34.8 32.4 32.8
>3 31.7 32.3 30.1 29.7
LABA use,c % 2.1 1.8 1.8 1.8
Leukotriene-receptor
antagonists use, %
1.0 0.8 0.4 0.2
Oral corticosteroids use, % 12.1 12.1 7.5 7.7
1 respiratory physician visit, % 6.0 7.0 5.9 5.9
1 ED visit for asthma, % 13.5 13.3 12.6 12.4
1 hospitalization
for asthma, %
1.2 1.2 1.5 1.5
Asthma severity,d %
Mild 81.5 82.1 82.2 82.3
Moderate 13.4 12.6 12.7 12.3
Severe 5.1 5.3 5.1 5.4
Asthma control,d %
Controlled 60.6 60.1 63.2 64.0
Uncontrolled 39.4 39.9 36.8 36.0
a ICS daily dose in beclomethasone-CFC equivalent over a 12-month period.
b SABA: short-acting inhaled beta2-agonist.
c LABA: long-acting inhaled beta2-agonist.
d Measured with validated database indexes that we developed based on medication use and the need for acute care for asthma.24
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and female fetuses.
On the other hand, our results are not in accordance
with those of three other smaller studies that found
increased markers of uncontrolled asthma among preg-
nancies of female fetuses,8e10 but the choice of the
outcome and the way it was measured can be put forward
to explain the differences between studies. In their blind-
controlled prospective study (nZ 34), Beecroft et al. have
found that asthmatic women pregnant with a female fetus
reported significantly more shortness of breath (72% vs
31%), nocturnal awakening (55% vs 37%), and general
asthma symptoms (50% vs 31%) than women pregnant with
a male fetus.8 However, these self-reported asthma
symptoms might not necessarily reflect asthma exacerba-
tions. Moreover, Dodds et al. have evaluated steroids use
during pregnancy among a sample of 817 pregnant asth-
matic women without having specific data on asthma
severity or symptoms and found that it was higher among
mothers of a female fetus as opposed to a male fetus (20%
vs 14%).9 This outcome is difficult to interpret since it is
unclear whether or not it includes only oral corticosteroids
or both inhaled and oral formulations, which in the lattercase would not necessarily reflect uncontrolled asthma.
Moreover, we cannot conclude on the statistical signifi-
cance of this difference since no statistical inference was
reported in the article. Finally, Kwon et al. used
a prospective cohort design to study an objective outcome
among 702 pregnant women with asthma, i.e. PEF
measures. The PEF was assessed at enrolment and at 21,
29, and 37 weeks of gestation. The 10% reported differ-
ence in log diurnal variation of PEF between pregnancies
of male and female fetuses reached statistical signifi-
cance, but we question the clinical significance of the
observed difference.10
Our study must be interpreted in the light of the
following limitations. First, the obtained data from the
administrative databases reflect medication dispensing and
might not correspond exactly to medication intake.
However, there is no reason to believe that the use of the
dispensed medications differed between mothers of female
and male fetuses. Secondly, the outcome was evaluated for
either trimesters or the entire pregnancy and this
precluded us to identify short-term changes in asthma
control. Thirdly, we did not have access to clinical data,
such as the frequency of asthma symptoms and lung
Table 3 Occurrence of maternal moderate to severe asthma exacerbation in each trimester and during the entire pregnancy,
by fetal gender.
n total At least
one exacerbation, n (%)
Crude OR
(F vs M)
Adjusted OR (95% CI)
(F vs M)
1st trimester F 5519 378 (6.9) 1.00 1.01 (0.86e1.18)a
M 5721 391 (6.8)
2nd trimester F 5519 381 (6.9) 0.98 0.98 (0.84e1.14)b
M 5721 408 (7.1)
3rd trimester F 5474 220 (4.0) 1.02 1.03 (0.85e1.24)c
M 5667 211 (3.7)
During pregnancy F 5519 846 (15.3) 1.02 1.02 (0.92e1.14)d
M 5721 861 (15.1)
F: female fetus, M: male fetus.
a Adjusted for respiratory specialist visit, asthma severity and asthma control in the year before pregnancy, and ICS use in the first
trimester of pregnancy.
b Adjusted for socioeconomic status, gestational diabetes, respiratory specialist visit, asthma severity in the year before pregnancy,
and ICS use in the second trimester of pregnancy.
c Adjusted for gestational diabetes, respiratory specialist visit, asthma severity in the year before pregnancy, and ICS use in the third
trimester of pregnancy.
d Adjusted for socioeconomic status, respiratory specialist visit during pregnancy, asthma severity and asthma control in the year
before pregnancy, and ICS use during pregnancy.
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a milder lack of control that could be perceived by the
mother.
Our study has also several strengths. One of the biggest
strengths is its very large sample size, which provided high
power to detect small differences. Indeed, we had 80%
power to detect a relative difference of 16% (i.e.
RRZ 1.16) in the rate of asthma exacerbations between
pregnancies of female and male fetus. Moreover, the data
obtained from the databases allowed us to identify
moderate to severe asthma exacerbations requiring
medical attention, which is an outcome that objectively
reflects an important aggravation of asthma symptoms. In
addition, our cohort included mothers with pregnanciesTable 4 Use of SABA during the entire pregnancy and within ea
n total At least one dose
per week [n (%)]
M
do
1st trimester F 5529 3083 (55.8) 4.
M 5728 3200 (55.9) 4.
2nd trimester F 5529 3058 (55.3) 4.
M 5728 3172 (55.4) 4.
3rd trimester F 5484 2864 (52.2) 4.
M 5674 2972 (52.4) 4.
During pregnancy F 5529 3456 (62.5) 4.
M 5728 3583 (62.6) 4.
F: female fetus, M: male fetus.
a Adjusted for socioeconomic status, high risk pregnancy, and respi
asthma severity and asthma control in the year before pregnancy.
b Adjusted for socioeconomic status and respiratory specialist visit d
asthma control in the year before pregnancy.
c Adjusted for socioeconomic status and respiratory specialist visit
asthma control in the year before pregnancy.
d Adjusted for socioeconomic status, high risk pregnancy, pregnan
pregnancy, and asthma severity and asthma control in the year beforwith alternate fetal gender allowing us to compare the
outcome between pregnancies of female and male fetuses
of the same mother, eliminating inter-patient variability.
In conclusion, we have shown that fetal gender had no
significant impact on the rate of maternal moderate to
severe asthma exacerbations, use of rescue medications,
and ICS during pregnancy. Fetal gender might have a minor
impact on maternal asthma symptoms, but this study
provides evidence that these changes are not serious
enough to lead to a moderate to severe exacerbation.
According to our results, it is not recommended to adjust
for fetal gender in epidemiologic studies in the field of
asthma and pregnancy. Moreover, our results suggest









4 0.09 0.07 (0.17 to 0.31)a
3
6 0.03 0.003 (0.27 to 0.26)b
5
5 0.02 0.06 (0.34 to 0.22)c
5
5 0.03 0.004 (0.23 to 0.24)d
4
ratory specialist visit during the first trimester of pregnancy, and
uring the second trimester of pregnancy, and asthma severity and
during the third trimester of pregnancy, and asthma severity and
cy induced hypertension and respiratory specialist visit during
e pregnancy.
Table 5 Use of ICS during the entire pregnancy and within each trimester, by fetal gender.






1st trimester F 5529 1933 (35.0) 76.5 1.55 1.17 (5.33;7.67)a
M 5728 1995 (34.8) 74.9
2nd trimester F 5529 1933 (35.0) 87.1 4.36 3.63 (3.82 to 11.09)b
M 5728 1974 (34.5) 82.8
3rd trimester F 5484 1788 (32.6) 99.3 4.36 3.01 (6.28 to 12.30)c
M 5674 1855 (32.7) 94.9
During pregnancy F 5529 2301 (41.6) 85.7 3.17 2.46 (4.01; 8.93)d
M 5728 2348 (41.0) 82.5
F: female fetus, M: male fetus.
a Adjusted for maternal age at conception, area of residency at delivery, chronic diabetes, chronic hypertension, number of prenatal
visits during the first trimester of pregnancy, respiratory specialist visit during the first trimester and asthma severity and asthma control
in the year before pregnancy.
b Adjusted for maternal age at conception, chronic diabetes, chronic hypertension, number of prenatal visits during the second
trimester of pregnancy, respiratory specialist visit during the second trimester and asthma severity in the year before pregnancy.
c Adjusted for maternal age at conception, chronic diabetes, chronic hypertension, number of prenatal visits during the third trimester
of pregnancy, respiratory specialist visit during the third trimester of pregnancy and asthma severity in the year before pregnancy.
d Adjusted for maternal age at conception, area of residency at delivery, gestational diabetes, chronic diabetes, chronic hypertension,
number of prenatal visits during pregnancy, respiratory specialist visit during pregnancy and asthma severity and asthma control in the
year before pregnancy.
150 F. Firoozi et al.the management of asthma during pregnancy, and that the
management should aim at asthma control regardless of the
gender of the fetus.
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